Malta

Malta

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.61 (0.50 - 0.72) 2019 Modelled IHME
0.61 (0.50 - 0.72) 2018 Modelled IHME
0.61 (0.49 - 0.74) 2017 Modelled IHME
0.62 (0.50 - 0.74) 2016 Modelled IHME
0.64 (0.51 - 0.77) 2015 Modelled IHME
0.65 (0.52 - 0.78) 2014 Modelled IHME
0.66 (0.54 - 0.78) 2013 Modelled IHME
0.67 (0.55 - 0.79) 2012 Modelled IHME
0.68 (0.56 - 0.80) 2011 Modelled IHME
0.68 (0.56 - 0.83) 2010 Modelled IHME
0.69 (0.57 - 0.83) 2009 Modelled IHME
0.7 (0.57 - 0.83) 2008 Modelled IHME
0.7 (0.58 - 0.84) 2007 Modelled IHME
0.71 (0.58 - 0.85) 2006 Modelled IHME
0.72 (0.59 - 0.86) 2005 Modelled IHME
0.72 (0.60 - 0.87) 2004 Modelled IHME
0.73 (0.60 - 0.88) 2003 Modelled IHME
0.74 (0.61 - 0.89) 2002 Modelled IHME
0.75 (0.61 - 0.90) 2001 Modelled IHME
0.75 (0.61 - 0.92) 2000 Modelled IHME
0.76 (0.63 - 0.92) 1999 Modelled IHME
0.77 (0.63 - 0.93) 1998 Modelled IHME
0.78 (0.64 - 0.93) 1997 Modelled IHME
0.79 (0.64 - 0.94) 1996 Modelled IHME
0.79 (0.64 - 0.95) 1995 Modelled IHME
0.8 (0.65 - 0.96) 1994 Modelled IHME
0.8 (0.66 - 0.97) 1993 Modelled IHME
0.81 (0.66 - 0.97) 1992 Modelled IHME
0.81 (0.66 - 0.98) 1991 Modelled IHME
0.81 (0.66 - 0.99) 1990 Modelled IHME
1.25 (0.15 - 9.32) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.06 (0.04 - 0.08) 2019 Modelled IHME
0.07 (0.04 - 0.09) 2018 Modelled IHME
0.07 (0.04 - 0.10) 2017 Modelled IHME
0.07 (0.04 - 0.10) 2016 Modelled IHME
0.07 (0.05 - 0.10) 2015 Modelled IHME
0.07 (0.05 - 0.10) 2014 Modelled IHME
0.08 (0.05 - 0.11) 2013 Modelled IHME
0.08 (0.06 - 0.11) 2012 Modelled IHME
0.09 (0.06 - 0.12) 2011 Modelled IHME
0.09 (0.06 - 0.13) 2010 Modelled IHME
0.09 (0.06 - 0.13) 2009 Modelled IHME
0.09 (0.06 - 0.13) 2008 Modelled IHME
0.1 (0.06 - 0.14) 2007 Modelled IHME
0.1 (0.06 - 0.14) 2006 Modelled IHME
0.1 (0.06 - 0.14) 2005 Modelled IHME
0.1 (0.06 - 0.14) 2004 Modelled IHME
0.1 (0.06 - 0.14) 2003 Modelled IHME
0.1 (0.06 - 0.14) 2002 Modelled IHME
0.1 (0.07 - 0.13) 2001 Modelled IHME
0.1 (0.07 - 0.13) 2000 Modelled IHME
0.13 (0.09 - 0.17) 1999 Modelled IHME
0.2 (0.14 - 0.26) 1998 Modelled IHME
0.29 (0.20 - 0.37) 1997 Modelled IHME
0.36 (0.24 - 0.47) 1996 Modelled IHME
0.4 (0.26 - 0.53) 1995 Modelled IHME
0.41 (0.27 - 0.54) 1994 Modelled IHME
0.41 (0.27 - 0.55) 1993 Modelled IHME
0.42 (0.28 - 0.56) 1992 Modelled IHME
0.42 (0.28 - 0.57) 1991 Modelled IHME
0.42 (0.28 - 0.57) 1990 Modelled IHME
0.39 (0.05 - 3.14) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (8 - 17) 2019 Modelled IHME
12 (8 - 17) 2018 Modelled IHME
12 (8 - 18) 2017 Modelled IHME
12 (8 - 18) 2016 Modelled IHME
12 (8 - 18) 2015 Modelled IHME
12 (8 - 18) 2014 Modelled IHME
12 (8 - 18) 2013 Modelled IHME
12 (8 - 18) 2012 Modelled IHME
12 (8 - 18) 2011 Modelled IHME
13 (9 - 18) 2010 Modelled IHME
13 (9 - 19) 2009 Modelled IHME
13 (9 - 19) 2008 Modelled IHME
13 (9 - 19) 2007 Modelled IHME
14 (9 - 20) 2006 Modelled IHME
14 (9 - 20) 2005 Modelled IHME
14 (9 - 20) 2004 Modelled IHME
14 (9 - 20) 2003 Modelled IHME
14 (9 - 20) 2002 Modelled IHME
14 (9 - 20) 2001 Modelled IHME
14 (10 - 20) 2000 Modelled IHME
14 (10 - 20) 1999 Modelled IHME
14 (10 - 20) 1998 Modelled IHME
14 (10 - 20) 1997 Modelled IHME
14 (10 - 21) 1996 Modelled IHME
14 (10 - 21) 1995 Modelled IHME
14 (10 - 21) 1994 Modelled IHME
14 (10 - 21) 1993 Modelled IHME
14 (10 - 21) 1992 Modelled IHME
14 (10 - 21) 1991 Modelled IHME
14 (10 - 21) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
88 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
95 2015 Survey/reported WHO/UNICEF
90 2014 Survey/reported WHO/UNICEF
94 2013 Survey/reported WHO/UNICEF
93 2012 Survey/reported WHO/UNICEF
82 2011 Survey/reported WHO/UNICEF
75 2010 Survey/reported WHO/UNICEF
86 2009 Survey/reported WHO/UNICEF
86 2008 Survey/reported WHO/UNICEF
82 2007 Survey/reported WHO/UNICEF
86 2006 Survey/reported WHO/UNICEF
85 2005 Survey/reported WHO/UNICEF
85 2004 Survey/reported WHO/UNICEF
89 2003 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
72 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.82 (0.67 - 1) 2019 Modelled IHME
0.81 (0.67 - 0.99) 2018 Modelled IHME
0.8 (0.65 - 0.98) 2017 Modelled IHME
0.79 (0.65 - 0.95) 2016 Modelled IHME
0.77 (0.63 - 0.94) 2015 Modelled IHME
0.77 (0.63 - 0.92) 2014 Modelled IHME
0.76 (0.62 - 0.92) 2013 Modelled IHME
0.76 (0.62 - 0.92) 2012 Modelled IHME
0.76 (0.62 - 0.92) 2011 Modelled IHME
0.76 (0.61 - 0.92) 2010 Modelled IHME
0.75 (0.61 - 0.92) 2009 Modelled IHME
0.75 (0.61 - 0.91) 2008 Modelled IHME
0.74 (0.61 - 0.91) 2007 Modelled IHME
0.74 (0.60 - 0.91) 2006 Modelled IHME
0.73 (0.60 - 0.91) 2005 Modelled IHME
0.73 (0.60 - 0.90) 2004 Modelled IHME
0.72 (0.59 - 0.89) 2003 Modelled IHME
0.71 (0.59 - 0.87) 2002 Modelled IHME
0.71 (0.58 - 0.87) 2001 Modelled IHME
0.7 (0.57 - 0.86) 2000 Modelled IHME
0.69 (0.57 - 0.85) 1999 Modelled IHME
0.69 (0.56 - 0.84) 1998 Modelled IHME
0.68 (0.56 - 0.83) 1997 Modelled IHME
0.67 (0.55 - 0.83) 1996 Modelled IHME
0.67 (0.55 - 0.83) 1995 Modelled IHME
0.67 (0.55 - 0.82) 1994 Modelled IHME
0.67 (0.54 - 0.82) 1993 Modelled IHME
0.67 (0.54 - 0.82) 1992 Modelled IHME
0.67 (0.54 - 0.82) 1991 Modelled IHME
0.67 (0.54 - 0.83) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
25.2 (13.10 - 37.30) 2014 Modelled Degenhardt L et al, 2017
13.8 (7.90 - 21.70) 2013 Survey/reported EMCDDA
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
40 (31 - 50) 2019 Modelled IHME
41 (31 - 50) 2018 Modelled IHME
41 (31 - 51) 2017 Modelled IHME
41 (31 - 51) 2016 Modelled IHME
41 (30 - 51) 2015 Modelled IHME
40 (30 - 51) 2014 Modelled IHME
40 (30 - 50) 2013 Modelled IHME
40 (30 - 50) 2012 Modelled IHME
40 (30 - 50) 2011 Modelled IHME
40 (30 - 50) 2010 Modelled IHME
40 (30 - 51) 2009 Modelled IHME
40 (30 - 50) 2008 Modelled IHME
40 (30 - 50) 2007 Modelled IHME
40 (30 - 50) 2006 Modelled IHME
40 (30 - 50) 2005 Modelled IHME
40 (30 - 51) 2004 Modelled IHME
41 (30 - 51) 2003 Modelled IHME
41 (30 - 51) 2002 Modelled IHME
41 (31 - 51) 2001 Modelled IHME
41 (31 - 51) 2000 Modelled IHME
41 (31 - 51) 1999 Modelled IHME
40 (30 - 51) 1998 Modelled IHME
40 (30 - 51) 1997 Modelled IHME
40 (30 - 51) 1996 Modelled IHME
41 (31 - 51) 1995 Modelled IHME
41 (31 - 51) 1994 Modelled IHME
41 (31 - 51) 1993 Modelled IHME
41 (31 - 51) 1992 Modelled IHME
41 (31 - 51) 1991 Modelled IHME
41 (31 - 51) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
72 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HCV elimination goal
Year of goal
2025

Prevalence (national)

Modelled

HBV (HBsAg+)
0.61 (%)
2019
(0.5 - 0.72(%))
IHME
HCV (RNA/cAg+)
0.82 (%)
2019
(0.67 - 1(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
5
2019
(4 - 7)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
15
2019
(12 - 19)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.06 (%)
2019, latest modelled
(0.04 - 0.08(%))
IHME

Prevalence PWID

HCV
13.80 (%)
2013, survey/surveillance
(7.90 - 21.70(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines